持续输注血管活性药物期间拔除侵入性机械通气
该回顾性队列研究纳入Calgary ICU中接受血管活性药物联合侵入性机械通气并尝试拔管的成人患者6140例,其中721例(11.7%)在持续使用血管活性药物时拔管,5419例(88.3%)在停用后拔管。主要暴露为拔管时继续使用血管活性药物,主要结局为96小时内再插管。总体上,使用血管活性药物时拔管与再插管风险增加无显著关联(SHR 1.81,95%CI 0.91-3.61;P=0.09),但死亡率(HR 1.22,95%CI 1.02-1.47;P=0.03)和住院时间延长(未出院SHR 0.78,95%CI 0.68-0.91;P<0.01)增加。亚组分析显示,高剂量血管活性药物(>0.1 μg/kg/min)时拔管与再插管风险增加相关(SHR 2.25,95%CI 1.01-4.98;P=0.046),而低剂量(≤0.1 μg/kg/min)时拔管与死亡率降低(HR 0.69,95%CI 0.51-0.91;P=0.01)和ICU住院时间缩短(SHR 1.34,95%CI 1.09-1.65;P=0.01)相关,再插管或住院时间无差异。
要点
- 高剂量血管活性药物(>0.1 μg/kg/min)时拔管与再插管风险增加相关(SHR 2.25,95%CI 1.01-4.98;P=0.046)。
- 低剂量血管活性药物(≤0.1 μg/kg/min)时拔管与死亡率降低相关(HR 0.69,95%CI 0.51-0.91;P=0.01)。
- 总体上使用血管活性药物时拔管与再插管风险增加无显著关联(SHR 1.81,95%CI 0.91-3.61;P=0.09),但死亡率增加(HR 1.22,95%CI 1.02-1.47;P=0.03)。
- 使用血管活性药物时拔管与住院时间延长相关(未出院SHR 0.78,95%CI 0.68-0.91;P<0.01)。
- 低剂量血管活性药物时拔管与ICU住院时间缩短相关(SHR 1.34,95%CI 1.09-1.65;P=0.01),再插管或住院时间无差异。
适用人群与场景
- Calgary ICU中接受血管活性药物联合侵入性机械通气并尝试拔管的成人患者。
研究设计与关键结果
- 回顾性队列研究,纳入6140例接受侵入性机械通气并使用血管活性药物的成人患者,其中721例(11.7%)在持续使用血管活性药物时拔管,5419例(88.3%)在停用后拔管。
- 主要结局:96小时内再插管;总体上使用血管活性药物时拔管与再插管风险增加无显著关联(SHR 1.81,95%CI 0.91-3.61;P=0.09)。
- 次要结局:死亡率增加(HR 1.22,95%CI 1.02-1.47;P=0.03),住院时间延长(未出院SHR 0.78,95%CI 0.68-0.91;P<0.01)。
- 亚组分析:高剂量血管活性药物(>0.1 μg/kg/min)时拔管与再插管风险增加相关(SHR 2.25,95%CI 1.01-4.98;P=0.046)。
- 亚组分析:低剂量血管活性药物(≤0.1 μg/kg/min)时拔管与死亡率降低相关(HR 0.69,95%CI 0.51-0.91;P=0.01),ICU住院时间缩短(SHR 1.34,95%CI 1.09-1.65;P=0.01),再插管或住院时间无差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,高剂量血管活性药物(>0.1 μg/kg/min)时拔管与再插管风险增加相关,低剂量(≤0.1 μg/kg/min)时拔管与死亡率降低和ICU住院时间缩短相关,但需进一步研究验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Weaning protocols for discontinuation of invasive mechanical ventilation often mandate resolution of shock. Whether extubation while receiving vasopressors is associated with harm is uncertain. Objectives: To examine whether extubation while still receiving vasopressors is associated with worse outcomes. Methods: We performed a retrospective cohort study of adults in Calgary ICUs who received vasopressors with invasive mechanical ventilation and an extubation attempt. The primary exposure was continued vasopressor use at extubation. The primary outcome was reintubation within 96 hours. Secondary outcomes included in-hospital mortality and ICU/hospital length of stay (LOS). We assessed associations of vasopressor use at extubation with outcomes using multivariable competing-risk (reintubation/LOS) and Cox proportional-hazards (mortality) models. Measurements and Main Results: Of 6,140 patients who received invasive mechanical ventilation while on vasopressors, 721 (11.7%) were extubated while receiving vasopressors, and 5,419 (88.3%) after discontinuation. Extubation on vasopressors was not, in aggregate, significantly associated with an increased hazard of reintubation (subhazard ratio [SHR], 1.81 [95% confidence interval, 0.91-3.61]; P = 0.09). Both mortality (hazard ratio, 1.22 [1.02-1.47]; P = 0.03) and time to hospital discharge (SHR for remaining hospitalized, 0.78 [0.68-0.91]; P < 0.01) were increased. Extubation on high-dose vasopressors (>0.1 μg/kg/min) was associated with a greater hazard of reintubation (SHR, 2.25 [1.01-4.98]; P = 0.046) compared with extubation after vasopressor discontinuation. Meanwhile, extubation on low-dose vasopressors (⩽0.1 μg/kg/min) was associated with a lower mortality (hazard ratio, 0.69 [0.51-0.91]; P = 0.01) and a shorter ICU LOS (SHR, 1.34 [1.09-1.65]; P = 0.01), but no difference in reintubation or hospital LOS as compared with those weaned off vasopressors. Conclusions: Extubation while receiving high-dose but not low-dose vasopressors was associated with an increased risk of reintubation.
参考来源
- Zarrabian B, Wunsch H, Stelfox HT, et al. Liberation from Invasive Mechanical Ventilation with Continued Receipt of Vasopressor Infusions. Am J Respir Crit Care Med. 2022. PMID: 35107416. doi:10.1164/rccm.202108-2004OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。